Epitalon Peptide Significantly Reduces Spontaneous Cancer Risk and Extends Lifespan in Mice

Cancer remains a formidable global health challenge, with spontaneous carcinogenesis representing the complex, multifactorial process of tumor development that naturally occurs with aging. The pineal gland, a small endocrine gland in the brain, is well-known for producing melatonin, a hormone with significant antioxidant and oncostatic properties. However, the therapeutic potential of synthetic pineal peptides, particularly epitalon, in modulating the incidence and progression of naturally occurring tumors and extending overall healthy lifespan in genetically predisposed mammalian models has not been thoroughly investigated, presenting a critical knowledge gap in geroprotective and anti-cancer research.

The study yielded compelling evidence for Epitalon's anti-carcinogenic and life-extending capabilities. The incidence of spontaneous tumors was significantly reduced in the Epitalon-treated group, demonstrating a remarkable 43% decrease compared to the control animals (p<0.01). Furthermore, the latency period for tumor appearance was substantially prolonged by an average of 2.5 months in the treated cohort, indicating a delay in cancer onset. > The most profound finding was a statistically significant 25% increase in the average lifespan of Epitalon-treated mice compared to their control counterparts (p<0.005), underscoring a broad geroprotective effect beyond just tumor suppression. Specifically, the incidence of mammary tumors, a hallmark of the C3H/He strain, dropped from 65% in the control group to 37% in the Epitalon group. The overall tumor burden, measured by the number and size of tumors per animal, was also reduced by 30% in the treated animals, alongside a 15% reduction in tumor growth rate.